Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | UGCG | Q16739 | 5/20 | 0.50 |
| ▸ | GBA2 | Q9HCG7 | 5/20 | 0.50 |
| ▸ | GBA1 | P04062 | 4/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | LCT | P09848 | 2/20 | 0.43 |
| ▸ | SI | P14410 | 2/20 | 0.43 |
| ▸ | MGAM | O43451 | 1/20 | 0.43 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1246210 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL8482826 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL6212152 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL96809 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL9684333 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL25208054 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL97795 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL814418 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL1007794 | 1.00 | L3MBTL1 (0.54) | L3MBTL1TDP1TSHRUGCGGBA2 | |
| SCHEMBL22906771 | 0.98 | L3MBTL1 (0.53) | L3MBTL1TDP1TSHRUGCGGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739652-A1 | LIPIDS AND COMPOSITIONS THEREOF | Kernal Biologics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | KERNAL BIOLOGICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-2788006-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4674856-A2 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | Alnylam Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| EP-4036079-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS | MODERNATX INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | MODERNATX, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-3254672-B1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12364762-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-12350338-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| EP-2268606-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| WO-2010115854-A1 | ELECTRONIC DEVICES COMPRISING NOVEL PHOSPHONIC ACID SURFACE MODIFIERS | GEORGIA TECH RESEARCH CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2009132978-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009132979-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-10-29 | — | — | US | disclosed |
| US-20090270500-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-10-29 | — | — | US | disclosed |
| EP-0743985-B1 | METHOD FOR PREPARING CYCLIC KETONES | FIRMENICH & CIE (CH) | 2000-10-11 | — | — | EP | disclosed |
| US-5667995-A | MICROORGANISM CULTURE, BETA-OXIDATION, BIOSYNTHESIS | FIRMENICH SA (CH) | 1997-09-16 | — | — | US | disclosed |
| EP-0743985-A1 | METHOD FOR PREPARING CYCLIC KETONES | FIRMENICH SA (CH) | 1996-11-27 | — | — | EP | disclosed |
| WO-1996018742-A1 | METHOD FOR PREPARING CYCLIC KETONES | FIRMENICH S.A. (CH) | 1996-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270505-A1 | 4-DIMETHYLAMINOBUTYRIC ACID DERIVATIVES | CPT1B, CPT1A, CPT2 | L3MBTL1 1452/4885TDP1 2013/4885TSHR 2935/4885 |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | L3MBTL1 2222/4885TDP1 4803/4885TSHR 70/4885 |
| US-20090270500-A1 | 4-TRIMETHYLAMMONIO-BUTYRATES AS CPT2 INHIBITORS | CPT1A, CPT1B, CPT2 | L3MBTL1 1676/4885TDP1 2520/4885TSHR 3172/4885 |
| US-12350338-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | L3MBTL1 1228/4885TDP1 1779/4885TSHR 2733/4885 |
| US-12396961-B2 | Compounds and compositions for intracellular delivery of agents | LNPK, PLTP, PHOSPHO1 | L3MBTL1 723/4885TDP1 3837/4885TSHR 3222/4885 |
| US-12364762-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | L3MBTL1 1228/4885TDP1 1779/4885TSHR 2733/4885 |
| US-20260116845-A1 | LIPIDS AND COMPOSITIONS THEREOF | LIPC, LIPA, NPC1L1 | L3MBTL1 295/4885TDP1 1579/4885TSHR 1603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.